Description
PURPOSE: To evaluate the long-term safety and efficacy of posterior chamber collagen copolymer
phakic intraocular lens (pIOL) implantation to correct myopia.
SETTING: Fern!andez-Vega Ophthalmological Institute, Oviedo, Spain.
DESIGN: Cohort study.
METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL
vault, endothelial cell loss, and adverse events were evaluated for 5 years after implantation of
the Visian Implantable Collamer Lens pIOL for moderate to high myopia.
RESULTS: The mean spherical equivalent (188 eyes) decreased from !11.17 diopters (D)G 3.40
(SD) preoperatively to!0.88G0.72 D 5 years postoperatively. The mean change in refraction from
1 month to 5 years was !0.65G0.65 D. The mean UDVA and CDVA (Snellen decimal) were 0.69G
0.26 and 0.83 G 0.15, respectively. The mean safety and efficacy indices were 1.27 G 0.33 and
0.89 G 0.35, respectively. No eye lost more than 2 lines of visual acuity; 70% achieved 0.80 or
better CDVA. Three eyes (1.6%) developed late anterior subcapsular cataract that was clinically
significant in 1 case, leading to pIOL removal and phacoemulsification. Of the 3 eyes (1.6%)
with a mild transient increase in intraocular pressure (up to 27 mm Hg), none required a second
surgical procedure or prolonged topical medication. The total endothelial cell loss (considered
cumulatively at consecutive intervals through 5 years) was 7.7%. There was a tendency toward
decreased pIOL vault decrease over time. No vision-threatening complications occurred.
CONCLUSION: Implantation of the collagen copolymer pIOL for moderate to high myopia was safe
and effective and provided long-term predictable, stable refractive results.
; Baamonde, Begoña 
